News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,598 Results
Type
Article (13726)
Company Profile (101)
Press Release (250771)
Section
Business (88020)
Career Advice (465)
Deals (15341)
Drug Delivery (66)
Drug Development (36585)
Employer Resources (49)
FDA (6286)
Job Trends (6194)
News (150169)
Policy (14023)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Adcomms (6)
Allergies (29)
Alliances (23206)
ALS (33)
Alzheimer's disease (379)
Antibody-drug conjugate (ADC) (34)
Approvals (6314)
Artificial intelligence (97)
Autoimmune disease (5)
Automation (3)
Bankruptcy (148)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (52)
Biotechnology (40)
Bladder cancer (17)
Brain cancer (15)
Breast cancer (72)
Cancer (541)
Cardiovascular disease (60)
Career advice (406)
Career pathing (10)
CAR-T (18)
Cell therapy (78)
Cervical cancer (4)
Clinical research (30805)
Collaboration (303)
Compensation (126)
Complete response letters (16)
COVID-19 (757)
CRISPR (18)
C-suite (103)
Cystic fibrosis (35)
Data (548)
Denatured (15)
Depression (9)
Diabetes (74)
Diagnostics (1311)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (52)
Drug pricing (62)
Drug shortages (12)
Duchenne muscular dystrophy (27)
Earnings (31946)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37310)
Executive appointments (334)
FDA (6635)
Featured Employer (20)
Friedreich's ataxia (2)
Funding (188)
Gene editing (35)
Generative AI (8)
Gene therapy (95)
GLP-1 (328)
Government (1282)
Grass and pollen (2)
Guidances (15)
Healthcare (3558)
Huntington's disease (4)
IgA nephropathy (8)
Immunology and inflammation (26)
Indications (11)
Infectious disease (788)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (36)
Interviews (59)
IPO (5873)
IRA (29)
Job creations (2050)
Job search strategy (372)
Kidney cancer (6)
Labor market (8)
Layoffs (175)
Leadership (3)
Legal (3428)
Liver cancer (19)
Lung cancer (74)
Lymphoma (49)
Machine learning (1)
Management (16)
Manufacturing (133)
MASH (28)
Medical device (1272)
Medtech (1274)
Mergers & acquisitions (9632)
Metabolic disorders (233)
Multiple sclerosis (16)
NASH (14)
Neurodegenerative disease (19)
Neuropsychiatric disorders (5)
Neuroscience (534)
NextGen: Class of 2025 (1585)
Non-profit (593)
Northern California (638)
Now hiring (7)
Obesity (133)
Opinion (116)
Ovarian cancer (18)
Pain (46)
Pancreatic cancer (13)
Parkinson's disease (41)
Partnered (5)
Patents (94)
Patient recruitment (26)
Peanut (9)
People (28811)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8017)
Phase II (13032)
Phase III (11694)
Pipeline (328)
Podcasts (44)
Policy (56)
Postmarket research (1401)
Preclinical (3196)
Press Release (25)
Prostate cancer (41)
Psychedelics (8)
Radiopharmaceuticals (119)
Rare diseases (154)
Real estate (2633)
Recruiting (17)
Regulatory (10040)
Reports (13)
Research institute (563)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (32)
Series A (32)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (651)
Special edition (6)
Sponsored (6)
Startups (1626)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6467)
Vaccines (143)
Venture capitalists (13)
Webinars (10)
Weight loss (91)
Women's health (8)
Worklife (3)
Date
Today (31)
Last 7 days (223)
Last 30 days (1085)
Last 365 days (12224)
2025 (2459)
2024 (12500)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (49)
Arkansas (3)
Asia (20038)
Australia (2598)
California (1550)
Canada (842)
China (198)
Colorado (63)
Connecticut (65)
Delaware (50)
Europe (39265)
Florida (284)
Georgia (34)
Idaho (9)
Illinois (170)
India (13)
Indiana (123)
Iowa (1)
Japan (79)
Kansas (54)
Kentucky (12)
Maine (2)
Maryland (237)
Massachusetts (1318)
Michigan (27)
Minnesota (84)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (671)
New Mexico (7)
New York (447)
North Carolina (366)
North Dakota (2)
Northern California (638)
Ohio (44)
Oklahoma (4)
Oregon (16)
Pennsylvania (388)
Puerto Rico (6)
Rhode Island (6)
South America (500)
South Carolina (2)
Southern California (651)
Tennessee (31)
Texas (205)
Utah (32)
Virginia (68)
Washington D.C. (29)
Washington State (107)
Wisconsin (14)
264,598 Results for "tremeau pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th
Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th.
October 20, 2022
·
3 min read
Genetown
Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX
Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatology’s (ACR) Convergence Meeting in Philadelphia.
November 11, 2022
·
3 min read
Drug Development
Tremeau Receives May Proceed Notification From FDA For Phase III Program in Acute Migraine For TRM-201 (Rofecoxib)
Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.
June 14, 2022
·
7 min read
Genetown
Tremeau Expands Pipeline with Novel Non-Opioid Compound for the Treatment of Acute Pain
Tremeau Pharmaceuticals today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/240,446. Once issued, the patent will provide composition of matter patent protection for Tremeau’s novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.
October 25, 2021
·
6 min read
Genetown
Tremeau Pharmaceuticals ASH 2021 Presentations Highlight Unmet Need for Non-Opioid Pain Treatments for Patients with Bleeding Disorders
Tremeau Pharmaceuticals will present three abstracts highlighting the need for new non-opioid treatment options for bleeding disorder patients during the 63rd American Society of Hematology Annual Meeting and Exposition in Atlanta.
December 13, 2021
·
4 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Genetown
Tremeau Pharmaceuticals Will Advance Non-Opioid Pain Program with Investment from Gurnet Point Capital
Investment will enable Tremeau to advance the clinical development of TRM-201 (rofecoxib) Tremeau has gained agreement with FDA to initiate a pivotal Phase III trial for TRM-201 in hemophilic arthropathy (HA), a painful and debilitating joint disease If approved, TRM-201 would potentially be the first new oral non-opioid pain treatment in over 15 years, and the first specifically indicated for HA
December 9, 2020
·
6 min read
Press Releases
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
March 5, 2025
·
1 min read
Press Releases
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
March 4, 2025
·
1 min read
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
1 of 26,460
Next
